Form 4: 4D Molecular Therapeutics Director Charles Theuer Granted 22,500 Stock Options

Director Charles Theuer of 4D Molecular Therapeutics, Inc. was granted 22,500 stock options at an exercise price of $4.15 as part of the company's non-employee director compensation program.

Summary

• Charles Theuer, a Director of 4D Molecular Therapeutics, Inc. (FDMT), was granted 22,500 stock options.
• The stock options were granted on June 17, 2025, with an exercise price of $4.15 per share.
• These options were automatically granted under the terms of the Company's non-employee director compensation program.
• The options will vest and become exercisable with respect to one-third (1/3) of the total shares on June 17, 2026, and in equal monthly installments thereafter.
• Full vesting of the options is scheduled for June 17, 2028, contingent on Mr. Theuer's continued service to the Issuer.
• Additionally, the stock options will vest in full upon the consummation of a Change in Control, as defined in the 2020 Incentive Award Plan.
• The expiration date for these stock options is June 16, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a routine, expected compensation event that aligns director interests with shareholders, without indicating any negative operational or financial issues.

Positives

• The grant of stock options aligns the interests of Director Charles Theuer with those of the shareholders, incentivizing long-term company performance.
• This is a routine compensation event, indicating stable corporate governance practices regarding director remuneration.

Future Outlook

The stock options are subject to a vesting schedule, with one-third vesting on June 17, 2026, and the remainder vesting in equal monthly installments until fully vested on June 17, 2028, contingent on continued service. Full vesting will also occur upon a Change in Control.

Management Comments

• The stock option was automatically granted pursuant to the terms of the Company's non-employee director compensation program.

Industry Context

The granting of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, serving as a standard component of compensation packages to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options as part of non-employee director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While the specific number of options and exercise price are unique to this grant, the mechanism aligns with typical compensation structures seen at comparable biopharmaceutical companies, which often use equity incentives to retain talent and align interests.
• Specific comparable companies or projects are not detailed within this Form 4 filing, as it focuses solely on the individual transaction.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Charles Theuer constitutes a related party transaction, as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continued service of Charles Theuer to the Issuer for the options to vest.
• Vesting of 1/3 of the options on June 17, 2026.
• Subsequent monthly vesting installments until full vesting on June 17, 2028.
• Potential full vesting upon a Change in Control event.

Key Dates

Keywords

SEC Form 4, Stock Option Grant, Director Compensation, Insider Transaction, 4D Molecular Therapeutics, FDMT, Equity Compensation, Vesting Schedule